> top > docs > PMC:7264098 > spans > 10406-12095 > annotations

PMC:7264098 / 10406-12095 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T209 205-213 SP_7 denotes COVID-19
T210 385-390 UBERON:0007023 denotes adult
T211 476-491 CHEBI:52217;CHEBI:52217 denotes pharmacological
T212 552-557 NCBITaxon:10239 denotes viral
T213 577-601 CHEBI:67079;CHEBI:67079 denotes anti-inflammatory agents
T214 669-677 GO:0035376 denotes entry of
T215 682-687 NCBITaxon:10239 denotes virus
T216 731-736 NCBITaxon:10239 denotes viral
T217 737-744 SO:0000704 denotes genetic
T218 763-769 UBERON:0002405;GO:0006955 denotes immune
T219 770-778 GO:0006955 denotes response
T220 858-866 SP_10 denotes SARS-CoV
T221 871-879 SP_9 denotes MERS-CoV
T222 1063-1071 SP_10 denotes SARS-CoV
T223 1238-1247 DG_29 denotes ribavirin
T224 1317-1321 SP_9 denotes MERS
T225 1543-1548 SP_6;NCBITaxon:9606 denotes human
T226 1603-1609 NCBITaxon:9606 denotes people
T19107 205-213 SP_7 denotes COVID-19
T18999 385-390 UBERON:0007023 denotes adult
T82295 476-491 CHEBI:52217;CHEBI:52217 denotes pharmacological
T38095 552-557 NCBITaxon:10239 denotes viral
T83805 577-601 CHEBI:67079;CHEBI:67079 denotes anti-inflammatory agents
T45166 669-677 GO:0035376 denotes entry of
T6847 682-687 NCBITaxon:10239 denotes virus
T60882 731-736 NCBITaxon:10239 denotes viral
T38954 737-744 SO:0000704 denotes genetic
T73828 763-769 UBERON:0002405;GO:0006955 denotes immune
T2948 770-778 GO:0006955 denotes response
T72804 858-866 SP_10 denotes SARS-CoV
T63585 871-879 SP_9 denotes MERS-CoV
T57772 1063-1071 SP_10 denotes SARS-CoV
T4874 1238-1247 DG_29 denotes ribavirin
T72833 1317-1321 SP_9 denotes MERS
T51389 1543-1548 SP_6;NCBITaxon:9606 denotes human
T46048 1603-1609 NCBITaxon:9606 denotes people

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
266 391-399 Species denotes patients Tax:9606
267 858-866 Species denotes SARS-CoV Tax:694009
268 871-879 Species denotes MERS-CoV Tax:1335626
269 1063-1071 Species denotes SARS-CoV Tax:694009
270 1543-1548 Species denotes human Tax:9606
271 1603-1609 Species denotes people Tax:9606
272 1238-1247 Chemical denotes ribavirin MESH:D012254
273 205-213 Disease denotes COVID-19 MESH:C000657245
274 779-791 Disease denotes inflammation MESH:D007249
275 1172-1176 Disease denotes ARDS MESH:D012128

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T73 424-427 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T74 698-703 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T19 424-427 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T80 205-213 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T81 779-791 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T82 858-866 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T83 858-862 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T84 1063-1071 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T85 1063-1067 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T86 1172-1176 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T113 17-23 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T114 59-60 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T115 424-427 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T116 682-687 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T117 698-703 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T118 956-960 http://purl.obolibrary.org/obo/CLO_0001185 denotes 2018
T119 1337-1341 http://purl.obolibrary.org/obo/CLO_0001185 denotes 2018
T120 1504-1505 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T121 1543-1548 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T36 577-601 Chemical denotes anti-inflammatory agents http://purl.obolibrary.org/obo/CHEBI_67079
T37 1238-1247 Chemical denotes ribavirin http://purl.obolibrary.org/obo/CHEBI_63580
T38 1252-1262 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T17 763-778 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T18 779-791 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T60 0-252 Sentence denotes Despite over 300 active and recruiting clinical trials and a number of trials already completed, there is still no robust evidence that any of the investigated therapeutics are effective as treatments for COVID-19 disease (Channappanavar et al., 2017).
T61 253-347 Sentence denotes Equally, there is no evidence to support prophylactic treatment either (Sanders et al., 2020).
T62 348-458 Sentence denotes However, there are only 29 trials in adult patients with placebo-controlled arm (Channappanavar et al., 2017).
T63 459-602 Sentence denotes Various types of pharmacological treatments are currently under investigation including anti-viral, anti-malarial and anti-inflammatory agents.
T64 603-792 Sentence denotes These therapies generally target the following processes: (1) the entry of the virus into host cells, (2) multiplication of the viral genetic material, and (3) immune response/inflammation.
T65 793-1026 Sentence denotes Most of these agents have been previously used as treatments for SARS-CoV and MERS-CoV, however the overall conclusions of the meta-analyses published in 2006 and 2018, respectively, did not support the use of any particular regimen.
T66 1027-1209 Sentence denotes In relation to the meta-analysis of SARS-CoV treatments, the authors systematically reviewed 54 treatment studies, 15 in vitro studies and three ARDS studies (Stockman et al., 2006).
T67 1210-1419 Sentence denotes Although the combination of ribavirin and interferon-based (IFN) treatments appears the most effective for MERS (Morra et al., 2018), this needs to be confirmed in randomized placebo-controlled trial settings.
T68 1420-1689 Sentence denotes In terms of vaccines, there are at least 115 vaccine candidates in development with a number of these already initiated in human trials, however we expect vaccines to be available to people under emergency use only in early 2021 (Callaway, 2020; Thanh Le et al., 2020).

2_test

Id Subject Object Predicate Lexical cue
32574317-28373583-31466304 246-250 28373583 denotes 2017
32574317-32282022-31466305 341-345 32282022 denotes 2020
32574317-28373583-31466306 452-456 28373583 denotes 2017
32574317-16968120-31466307 1203-1207 16968120 denotes 2006
32574317-29664167-31466308 1337-1341 29664167 denotes 2018
32574317-32346146-31466309 1660-1664 32346146 denotes 2020
32574317-32273591-31466310 1683-1687 32273591 denotes 2020

MyTest

Id Subject Object Predicate Lexical cue
32574317-28373583-31466304 246-250 28373583 denotes 2017
32574317-32282022-31466305 341-345 32282022 denotes 2020
32574317-28373583-31466306 452-456 28373583 denotes 2017
32574317-16968120-31466307 1203-1207 16968120 denotes 2006
32574317-29664167-31466308 1337-1341 29664167 denotes 2018
32574317-32346146-31466309 1660-1664 32346146 denotes 2020
32574317-32273591-31466310 1683-1687 32273591 denotes 2020